Unknown

Dataset Information

0

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.


ABSTRACT: PURPOSE:To evaluate systematically in real clinical settings whether functional genetic variations in drug metabolizing enzymes influence optimized doses, efficacy, and safety of antipsychotic medications. METHODS:DNA was collected from 750 patients with chronic schizophrenia treated with five antipsychotic drugs (olanzapine, quetiapine, risperidone, ziprasidone, and perphenazine) as part of the Clinical Antipsychotic Trials of Intervention Effectiveness study. Doses for each of the medicines were optimized to 1, 2, 3, or 4x units in identically appearing capsules in a double-blind design. We analyzed 25 known functional genetic variants in the major and minor metabolizing enzymes for each medication. These variants were tested for association with optimized dose and other relevant clinical outcomes. RESULTS:None of the tested variants showed a nominally significant main effect in association with any of the tested phenotypes in European-Americans, African-Americans, or all patients. Even after accounting for potential covariates, no genetic variant was found to be associated with dosing, efficacy, overall tolerability, or tardive dyskinesia. CONCLUSION:There are no strong associations between common functional genetic variants in drug metabolizing enzymes and dosing, safety, or efficacy of leading antipsychotics, strongly suggesting merely modest effects on the use of these medicines in most patients in typical clinical settings.

SUBMITTER: Grossman I 

PROVIDER: S-EPMC3697113 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.

Grossman Iris I   Sullivan Patrick F PF   Walley Nicole N   Liu Youfang Y   Dawson Jeffrey R JR   Gumbs Curtis C   Gaedigk Andrea A   Leeder J Steven JS   McEvoy Joseph P JP   Weale Michael E ME   Goldstein David B DB  

Genetics in medicine : official journal of the American College of Medical Genetics 20081001 10


<h4>Purpose</h4>To evaluate systematically in real clinical settings whether functional genetic variations in drug metabolizing enzymes influence optimized doses, efficacy, and safety of antipsychotic medications.<h4>Methods</h4>DNA was collected from 750 patients with chronic schizophrenia treated with five antipsychotic drugs (olanzapine, quetiapine, risperidone, ziprasidone, and perphenazine) as part of the Clinical Antipsychotic Trials of Intervention Effectiveness study. Doses for each of t  ...[more]

Similar Datasets

| S-EPMC2652489 | biostudies-literature
| S-EPMC3845218 | biostudies-literature
| S-EPMC4258179 | biostudies-literature
| S-EPMC5054869 | biostudies-other
| S-EPMC7028971 | biostudies-literature
| S-EPMC10999740 | biostudies-literature
| S-EPMC4094113 | biostudies-literature
| S-EPMC4308551 | biostudies-literature
| S-EPMC7441561 | biostudies-literature
| S-EPMC5474154 | biostudies-literature